The world-first CESSATE Stop Smoking Study will compare two quitting aids (Desmoxan and Champix) to find out if both medications work equally as well as each other, or if one is more effective for stopping smoking. The benefits for participants include:
This project attempts to understand the global epidemiology of infectious disease among prisoners in all countries.
NDARC has been invited to undertake research in partnership with NSW Aboriginal drug and alcohol Residential Rehabilitation Services. This research is unique in being embedded into the routine delivery of their services.
Smoking is a leading cause of preventable disease and death.
Substance use among pregnant women is a significant public health issue. A range of adverse effects have been noted including increased risk of miscarriage and still birth, reduction in fetal growth, birth defects, developmental delay, growth retardation and neurological abnormalities.
Substance use amongst adolescents (those in the age group of 10-19) is an important public health issue in many countries of the region.
The Northern Territory prison population comprises 92% Indigenous Australians and 88% smokers. The NT prison-smoking ban creates a population-wide abstinence. We aim to extend this period of abstinence into the community.
Rationale
This project will estimate the social and economic costs related to tobacco use in NSW for 2014. Mortality and morbidity costs attributable to smoking will be estimated as will lost productivity, costs due to fires and the intangible costs due to mortality attributable to smoking.
Tobacco smoking is a leading cause of preventable disease and death. Smoking rates are higher among disadvantaged Australians and facilitating smoking cessation in this group is a national health priority.
This study aimed to examine the feasibility of agonist maintenance treatment for the major psychoactive drug classes: opioids, nicotine, benzodiazepines, cannabis, psychostimulants and alcohol.
